Pfizer's ALO-02 meets in Phase III pain trial

Pfizer Inc. (NYSE:PFE) said ALO-02 met the primary endpoint of improving pain scores from baseline to the final two weeks of the 12-week treatment period vs. placebo in a Phase III trial to treat mode...